Methods For Predicting The Survival Time Of Patients Suffering From Cancer


The present invention relates to methods for predicting the survival time of patients suffering from cancer. Neutral sphingomyelinase 2 (nSMase2), encoded by SMPD3, catalyzes sphingomyelin breakdown to ceramide. The inventors showed that SMPD3 is frequently downregulated in human metastatic melanoma, likely contributing to immune escape mechanisms and shortened overall survival. Mechanistically, they found that nSMase2 augmented the immunogenicity of melanoma cell-derived exosomes, by increasing their association with miR-155, a major pro-inflammatory miRNA. In particular, the present invention relates to a method for predicting the survival of a patient suffering from cancer comprising determining the expression level of miR-155 in a tumor sample obtained from the patient.

Download PDF
Document Preview
Document History
  • Publication: Mar 15, 2018
  • Application: Sep 11, 2017
    WO EP 2017072780 W
  • Priority: Sep 12, 2016
    EP EP 16306139 A

Download Citation

Sign in to the Lens